Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Venetoclax and magrolimab for treatment of AML and MDS

Jan Philipp Bewersdorf, MD, Yale School of Medicine, New Haven, CT, looks at the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax and justifies its use in the frontline setting, especially for patients with high-risk myelodysplastic syndrome (MDS) and high blast count. Currently, there are Phase I and II studies exploring its use when hypomethylating agents (HMAs) fail, and response to venetoclax has been seen. Magrolimab is an anti-CD47 monoclonal antibody with the potential in treating high-risk myelodysplastic syndrome (MDS). In combination with azacitidine, it is being investigated in a Phase III clinical trial. This interview took place during the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.